INTRODUCTION {#s1}
============

The cerebral vasculature plays an essential role in maintaining the homeostasis of the brain by providing oxygen and nutrients and removing waste products. During development, new branches of the cerebral vasculature are formed through angiogenesis by endothelial cells, the primary cell component of the vasculature, via complex cell-cell interactions and signaling pathways from existing vessels ([@DMM037044C82]). The cerebral vasculature also contributes to the formation of the neurovascular unit (NVU), which comprises pericytes, astrocytes, microglia and neurons in addition to endothelial cells. Compromise of the normal development or function of the NVU has been implicated in childhood brain development disorders and adult neurological dysfunction ([@DMM037044C65]; [@DMM037044C90]). In the NVU, cerebral endothelial cells, connected mainly by tight junction proteins, build the blood-brain barrier that acts as a primary semipermeable barrier and confers a high selectivity for molecular exchanges between the blood and the brain parenchyma ([@DMM037044C14]). Therefore, the inappropriate development of cerebral endothelial cells may lead to defects in angiogenesis and/or endothelial permeability, which are closely linked to vascular pathologies such as vascular malformations and stroke ([@DMM037044C20]; [@DMM037044C62]).

The development of the brain vasculature is coordinated by various extra- and intracellular signals. Among them, calcium signaling is one of the major regulators of vascular development and related pathogenesis. Vascular endothelial growth factor signals and various stimuli trigger the change of intracellular Ca^2+^ levels that act as second messengers in endothelial cells, which in turn affect the activity of transcription factors for angiogenesis, such as nuclear factor of activated T-cells, via Ca^2+^-dependent calmodulin/calcineurin activity ([@DMM037044C36]; [@DMM037044C49]). In addition, an overload of Ca^2+^ can cause endothelial barrier dysfunction; intracellular Ca^2+^ release via activation of IP~3~ receptors (IP3R) or ryanodine receptors (RyRs) of the endoplasmic reticulum into the cytoplasm can increase vascular permeability through disorganization of VE-cadherin (Cdh5) or cytoskeletal rearrangement ([@DMM037044C23]; [@DMM037044C73]; [@DMM037044C80]). Intriguingly, it has been reported that calcium supplementation for bone health can unexpectedly induce stroke and cardiovascular diseases ([@DMM037044C68]), and calcium channel blockers and calcium antagonists have been clinically used as therapeutic agents for strokes and blood vessel dysfunction ([@DMM037044C39]). Thus, understanding the detailed underlying molecular mechanisms of Ca^2+^ signaling in angiogenesis and vascular permeability along with the identification of key players may provide an important therapeutic means for treating vascular diseases.

Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a serine-threonine kinase that has a dual kinase activity capable of autophosphorylating its own tyrosine residues and phosphorylating other substrates. The *DYRK1A* gene was first identified in a *Drosophila* screening as a mutant *minibrain*, named for the brain morphology defects with reduced brain size ([@DMM037044C76]). *DYRK1A* is located in a Down syndrome critical region (DSCR) and is best known as a major causative gene that is implicated in brain function, neurological defects and neurofibrillary tangle formation in Down syndrome (DS) ([@DMM037044C48]; [@DMM037044C87]).

Interestingly, epidemiological studies suggested that DS patients have a reduced incidence of angiogenesis-related solid tumors ([@DMM037044C32]; [@DMM037044C59]) and carry numerous vascular anomalies such as umbilico-portal system anomalies, vertebral and right subclavian artery defects, and pulmonary vein stenosis ([@DMM037044C27]; [@DMM037044C64]; [@DMM037044C67]; [@DMM037044C75]). Furthermore, they also have an increased incidence of Moyamoya disease and cerebral amyloid angiopathy, which are associated with a cerebrovascular dysfunction and intracerebral hemorrhage ([@DMM037044C13]; [@DMM037044C18]; [@DMM037044C41]; [@DMM037044C56]; [@DMM037044C71]). Consistent with the potential role of *DYRK1A* in angiogenesis, the TS65Dn mouse model of DS, trisomic for the *Dyrk1a* gene, exhibited reduced tumor growth, presumably by suppressing tumor angiogenesis ([@DMM037044C3]). Although vascular defects had not been directly associated with human *DYRK1A* haploinsufficiency syndrome, it has been reported that nearly 75% of children with autism, some of which may have *DYRK1A* mutations or its reduced activity ([@DMM037044C44]), exhibited hypoperfusion in the brain detected by neuroimaging ([@DMM037044C7]; [@DMM037044C89]). Also, retinal angiogenesis is disrupted in *Dyrk1a* heterozygote mice ([@DMM037044C70]), suggesting a role of *DYRK1A* loss-of-function in regulating angiogenesis in the brain. Taken together, *DYRK1A* may be implicated in vascular formation and/or function, and this could provide a new perspective to understanding *DYRK1A*-related pathogenesis; however, *in vivo* evidence of *DYRK1*A function in vascular pathology is scarce.

To investigate the role of *DYRK1A* in vascular formation, we adopted developing zebrafish as a model organism. Zebrafish is a vertebrate animal model used for genetic studies of human diseases exhibiting a high similarity to humans at anatomical and molecular levels, especially in the vascular and nervous system ([@DMM037044C40]; [@DMM037044C72]). Zebrafish embryos can be readily manipulated for genetic gain-of-function studies with transgenesis or mRNA overexpression, and loss-of-function studies with gene knockouts or morpholino use ([@DMM037044C11]; [@DMM037044C37]; [@DMM037044C79]; [@DMM037044C84]; [@DMM037044C91]). Large clutch sizes and various inexpensive and fast experimental techniques allow the use of zebrafish for unique high-throughput *in vivo* small molecule screening, which enables the identification of hit compounds and gives insights into potential underlying mechanisms ([@DMM037044C51]).

We have recently reported autistic behavioral phenotypes of knockout mutants of *dyrk1aa*, a mammalian *DYRK1A* homolog, named *dyrk1aa^krb1^*, generated by transcription activator-like effector nucleases ([@DMM037044C44]). In the current study, we investigated a role of *DYRK1A* in cerebrovascular development during embryogenesis using the *dyrk1aa* loss-of-function mutants. The *dyrk1aa^krb1^* mutants exhibited cerebral hemorrhage and angiogenic defects in the developing hindbrain, as analyzed at high resolution by confocal fluorescent microscopy using transgenic animals and transmission electron microscopy. These vascular abnormalities were rescued by expression of wild-type (WT) *dyrk1aa* mRNA, but not a kinase-dead form, indicating an essential role of its kinase activity. Chemical screening using a US Food and Drug Administration (FDA)-approved chemical library identified the calcium chelator ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA) that efficiently rescued cerebral hemorrhage as well as abnormal cerebrovascular defects in *dyrk1aa* mutants. Another calcium signaling modulator, FK506, rescued the hemorrhagic and cerebrovascular defects of *dyrk1aa* mutants in a similar manner as EGTA, and transcriptomic analyses identified changes in calcium signaling as the main pathway affected in *dyrk1aa* mutants. Together, the cerebral hemorrhage and cerebrovascular defects of zebrafish *dyrk1aa* mutants and the chemical screening revealed an important but less-known role of *DYRK1A* in *in vivo* vascular formation, which involves a mechanism that is mediated by calcium signaling, providing a potential therapeutic target for *DYRK1A*-related vascular disorders.

RESULTS {#s2}
=======

Cerebral hemorrhage and a vascular phenotype of *dyrk1aa^krb1^* mutant embryos {#s2a}
------------------------------------------------------------------------------

We recently reported the generation of the *dyrk1aa^krb1^* mutants that displayed microcephaly and autistic behavioral phenotypes in adults, whereas no distinct morphological defects were observed during embryogenesis ([@DMM037044C44]). Detailed inspection of *dyrk1aa^krb1^* homozygous mutant embryos, however, revealed a cerebral hemorrhage phenotype as early as 52 h postfertilization (hpf) (arrows in [Fig. 1](#DMM037044F1){ref-type="fig"}A). Of the offspring of *dyrk1aa^krb1^* mutants, 27.9% of a clutch displayed cerebral hemorrhage, whereas less than 9.9% of WT offspring showed spontaneous hemorrhage at 52 hpf using *o*-dianisidine staining, which detects hemoglobin activity and allows observation of cerebral hemorrhage more closely ([Fig. 1](#DMM037044F1){ref-type="fig"}B). Spontaneous hemorrhage of WT offspring at 52 hpf was detected in less than 5% of the clutch under the brightfield microscope (without *o*-dianisidine staining, data not shown). Cerebral hemorrhage was detected as patches in the forebrain, midbrain, hindbrain and retina, with some embryos exhibiting multiple hemorrhages simultaneously ([Fig. 1](#DMM037044F1){ref-type="fig"}A). To obtain more pronounced hemorrhagic effects and observe a more explicit phenotype, we challenged the mutant embryos with heat stress by incubation at 35°C for 2.5 h from 48 hpf to 50.5 hpf, followed by keeping them at 28.5°C until 52 hpf. The following experiments for hemorrhagic phenotype were performed in the heat stress condition. It has been previously reported that cardiovascular stress aggravates the hemorrhagic phenotype in the brain, presumably by increasing the heart rate ([@DMM037044C5]; [@DMM037044C86]). Consistently, the cerebral hemorrhage of WT and *dyrk1aa^krb1^* mutants under the heat-stressed condition increased by 16.3% and 40.5%, respectively ([Fig. 1](#DMM037044F1){ref-type="fig"}B, Heat-stressed). Fig. 1.***dyrk1aa^krb1^* mutant embryos show cerebral hemorrhagic phenotype and abnormal development of CtAs in the brain.** (A) Cerebral hemorrhage was observed in *dyrk1aa^krb1^* mutant embryos (*dyrk1aa^krb1^*) at 52 hpf (Ac-Af, arrows) compared to WT (Aa, Ab). Aa,Ac,Ae show the lateral view; Ab,Ad,Af show the dorsal view. (B) Embryonic cerebral hemorrhage of WT occurred spontaneously in 9.9% of embryos, whereas *dyrk1aa^krb1^* embryos showed cerebral hemorrhage of 27.9% penetrance (Normal), using *o*-dianisidine staining. The cerebral hemorrhage of WT and *dyrk1aa^krb1^* mutants increased up to 16.3% and 40.5%, respectively, by inducing heat stress with 2.5 h incubation at 35°C from 48-50.5 hpf (Heat-stressed). The mean percentages for each genotype were presented from four independent experiments with approximately 20 embryos for each repeat. (C) Confocal fluorescent images at 52 hpf showing the development of CtAs in WT and *dyrk1aa^krb1^* mutant embryos in the *Tg(kdrl:EGFP)* background. (D) The lengths and branching points of CtAs in *dyrk1aa^krb1^* mutants were reduced down to 70.2% and 73.3%, respectively, compared to the WT embryos as 100% at 52 hpf. \**P*\<0.05, \*\*\**P*\<0.005 (Mann--Whitney *U* test). Data are mean±s.e.m. fb, forebrain; mb, midbrain; hb, hindbrain; e, eye; y, yolk. Scale bar: 250 µm in A; 50 µm in C.

Because cerebral hemorrhage is sometimes accompanied by defective cerebrovascular formation ([@DMM037044C2]), we examined the formation of central arteries (CtAs) in the hindbrain, a well-characterized stereotypical developing cerebrovascular structure, using *Tg(kdrl:EGFP)* transgenic animals ([@DMM037044C83]) in the WT or *dyrk1aa^krb1^* mutants. CtAs sprouted from the primordial hindbrain channels, which contained the pool of endothelial cells required for CtA formation, and invaded the hindbrain between 32 and 36 hpf with a stereotypical morphology within rhombomeres, formed with over 50% ipsilateral CtA connectivity at 48 hpf ([@DMM037044C8]; [@DMM037044C83]). A detailed, high-resolution confocal imaging analysis to compare the CtA formation of *dyrk1aa^krb1^* mutants and WT at 52 hpf revealed that the stereotypical structure of CtAs was abolished in *dyrk1aa^krb1^* mutant embryos ([Fig. 1](#DMM037044F1){ref-type="fig"}C). To quantitate the CtA vascular defects, the length and branching points of CtAs were measured, representing the migration/proliferation and sprouting activities of CtA endothelial cells, respectively ([@DMM037044C1]; [@DMM037044C63]; [@DMM037044C78]) ([Fig. 1](#DMM037044F1){ref-type="fig"}D). In *dyrk1aa^krb1^* mutants, the total lengths and branching points of CtAs were reduced to 70.2% and 73.3% compared to the WT control, respectively ([Fig. 1](#DMM037044F1){ref-type="fig"}D). In the following experiments, we used the length and branching points of CtAs as quantitative measures of defects in vascular development.

CtA angiogenic defects were also confirmed by examining RNA expression of vascular markers *kdrl* (*vegfr2*) and *dll4* by whole-mount RNA *in situ* hybridization (WISH) at various developmental stages including 30, 36 and 52 hpf ([Fig. S1](Fig. S1), *kdrl* and *dll4*). Consistent with the angiogenic defects revealed by *Tg(kdrl:EGFP)* transgenic animals, expression of *kdrl* and *dll4* in the vasculature of the hindbrain was reduced in *dyrk1aa^krb1^* mutant embryos at all stages examined (red arrows in [Fig. S1](Fig. S1), *kdrl* and *dll4*). These vascular defects in mutants appeared not to be due to gross defects of brain development because the expression of *krox20*, which marks rhombomere boundaries ([@DMM037044C57]; [@DMM037044C61]), and *isl1*, which labels primary motoneurons in the hindbrain ([@DMM037044C19]; [@DMM037044C38]; [@DMM037044C45]), were grossly unaffected in mutant embryos ([Fig. S1](Fig. S1), *krox20* and *isl1*). These vascular defects appeared not to be due to defective heart development or reduced blood flow, based on the normal heartrate of mutants compared to the WT embryos ([Fig. S2](Fig. S2), [Movies 1](Movies 1) and [2](2)).

Zebrafish *dyrk1aa* and *dyrk1ab*, mammalian *DYRK1A* orthologs, are expressed in endothelial cells and the nervous system during development {#s2b}
---------------------------------------------------------------------------------------------------------------------------------------------

We examined transcripts of *dyrk1aa* in zebrafish embryos using WISH during embryogenesis. *dyrk1aa* mRNA had a broad expression in the forebrain (black arrowheads/brackets), midbrain (gray arrowheads/brackets), hindbrain (blue arrowheads/brackets), spinal cord (orange arrowheads), heart (asterisks) and retina (red arrows) at 24, 48 and 72 hpf ([Fig. 2](#DMM037044F2){ref-type="fig"}Aa-Al). Transverse sections of WISH embryos at the midbrain level showed that *dyrk1aa* was broadly expressed in the tectum (green arrows), tegmentum (black arrow), the ganglionic cell layer (purple arrows) and the inner nuclear layer of the retina (red arrows) ([Fig. 2](#DMM037044F2){ref-type="fig"}Am,An). We also checked the expression patterns of *dyrk1ab* mRNA (ZFIN ID: ZDB-GENE-030131-5677), another zebrafish ortholog of human *DYRK1A*, using WISH, which appeared to be significantly overlapped with those of *dyrk1aa* ([Fig. S3](Fig. S3)). Fig. 2.**Zebrafish *dyrk1aa* and *dyrk1ab* are expressed in the developing brain during embryogenesis and detected in endothelial cells of the vasculature.** (A) WISH showed that *dyrk1aa* was expressed in the forebrain (black arrowheads, Aa-Af; black brackets, Ag-Al), the midbrain (gray arrowheads, Aa-Af; gray brackets, Ag-Al), the hindbrain (blue arrowheads, Aa-Af; blue brackets, Ag-Al) at 24, 48 and 72 hpf, and the spinal cord (orange arrowheads, Aa and Ab) at 24 hpf. It was also detected in the heart (black asterisks, Ad,Af,Aj,Al) and in the retina (red arrows, Ai-Al) at 48 and 72 hpf. Am and An are sectioned images of WISH embryos showing the expression of *dyrk1aa* in the tectum (green arrows), tegmentum (black arrow), the ganglionic cell layer (purple arrows) and the inner nuclear layer of the retina (red arrows) at 48 hpf and 72 hpf. See [Fig. S3](Fig. S3) for WISH of *dyrk1ab*. (B) Semi-quantitative RT-PCR analysis of *dyrk1aa* and *dyrk1ab* mRNA expression in whole embryos at indicated developmental stages. *dyrk1aa* and *dyrk1ab* expression was observed at the one-cell stage followed by diminishing at 6 hpf and resuming after 24 hpf. (C) Semi-quantitative RT-PCR analysis using endothelial cells isolated by FACS for sorting GFP-positive and -negative cells of *Tg(kdrl:EGFP)* embryos at 48 hpf revealed that *dyrk1aa* and *dyrk1ab* mRNAs were expressed in GFP-positive endothelial cells as well as in GFP-negative embryonic cells. Scale bars: 200 µm in Aa-Al; 50 µm in Am,An.

The temporal expression patterns of *dyrk1aa* and *dyrk1ab* mRNAs according to developmental stages by reverse transcription-PCR (RT-PCR) were also examined. Transcripts of *dyrk1aa* and *dyrk1ab* mRNA were strongly detectable at the one-cell stage but decreased after 6 hpf, presumably because of the maternal effect ([@DMM037044C31]; [@DMM037044C54]) ([Fig. 2](#DMM037044F2){ref-type="fig"}B). Zygotic *dyrk1aa* and *dyrk1ab* expression appeared to start at ∼15 hpf, increasing at 24 hpf, and strong expression was maintained until 5 days postfertilization (dpf) ([Fig. 2](#DMM037044F2){ref-type="fig"}B).

Furthermore, whether *dyrk1aa* and *dyrk1ab* mRNA was specifically expressed in endothelial cells was confirmed by performing RT-PCR analyses using GFP-positive *Tg(kdrl:EGFP)* endothelial cells isolated by fluorescence-activated cell sorting (FACS). The *dyrk1aa* and *dyrk1ab* mRNA was enriched in GFP-positive endothelial cells but was also expressed in GFP-negative cells, suggesting a role in endothelial as well as non-endothelial cells ([Fig. 2](#DMM037044F2){ref-type="fig"}C). These expression patterns were consistent with the reported mammalian *Dyrk1a* expression in the heart primordium and the central nervous system of developing mouse embryos, including the inner (neural) layer of the optic cup ([@DMM037044C30]; [@DMM037044C66]), and endothelial cells isolated from *Dscr1* transgenic mice, as assessed using western blotting ([@DMM037044C3]), suggesting a functional conservation across species. Recently, the expression of DYRK1A at the protein and RNA level in human endothelial cells and in mouse lung endothelial cells has also been shown by [@DMM037044C70].

Rescuing *dyrk1aa^krb1^* mutant phenotypes by *dyrk1aa* expression {#s2c}
------------------------------------------------------------------

To confirm that loss of function of the *dyrk1aa* gene was responsible for *dyrk1aa^krb1^* mutant phenotypes, we tested whether WT *dyrk1aa* mRNA rescued the cerebral hemorrhage and aberrant vascular phenotype in *dyrk1aa^krb1^* mutants by globally expressing full-length WT *dyrk1aa* mRNA. Using *o*-dianisidine staining, the high incidence of cerebral hemorrhage in *dyrk1aa^krb1^* mutants under heat stress (41.7% of the offspring) was shown to be significantly reduced down to 25.4% by 0.1 ng *dyrk1aa* mRNA injection ([Fig. 3](#DMM037044F3){ref-type="fig"}A,B), whereas the same dose injected into the WT background had little effect ([Fig. 3](#DMM037044F3){ref-type="fig"}A,C). Similarly, the reduced mean percentages of lengths (66.5%) and branching points (61.2%) of CtAs in *dyrk1aa^krb1^* mutants relative to WT controls (100%) were rescued (89.9% and 122%, respectively) with the expression of 0.1 ng *dyrk1aa* mRNA ([Fig. 3](#DMM037044F3){ref-type="fig"}D,E). The rescue of CtA angiogenesis defects were effective only within specific dose ranges of *dyrk1aa* mRNA expression in *dyrk1aa^krb1^* mutants, and overexpression of *dyrk1aa* mRNA in WT background increased CtA formation in a dose-dependent manner ([Fig. 3](#DMM037044F3){ref-type="fig"}E), suggesting the importance of spatial and temporal contexts for effects of *dyrk1aa* expression as well as its dose-sensitive nature. Fig. 3.**The cerebral hemorrhage and CtA angiogenic defects in *dyrk1aa^krb1^* mutants can be rescued by *dyrk1aa* expression, with the kinase activity of Dyrk1aa required for its phenotypic rescues.** (A) The *o*-dianisidine staining images at 52 hpf showed that the cerebral hemorrhage (arrows) of *dyrk1aa^krb1^* embryos was rescued by WT *dyrk1aa* mRNA expression, but not in no-injection control, *K193R-dyrk1aa* or *mCherryRed* mRNA. (B) The frequency of cerebral hemorrhage of *dyrk1aa^krb1^* was reduced from 41.7% to 25.4% by injecting WT *dyrk1aa* mRNA of 0.1 ng, but not significantly changed by injecting *K193R-dyrk1aa* or *mCherryRed* mRNA at 52 hpf. (C) Injection of mRNAs of WT *dyrk1aa*, *K193R-dyrk1aa* or *mCherryRed* control did not affect the cerebral hemorrhage in WT embryos at 52 hpf. The mean percentages for each genotype were presented from three independent experiments with approximately 20 embryos in each repeat. (D) The compiled images of CtAs of *Tg(kdrl:EGFP)* at 52 hpf by confocal microscopy showed that the angiogenic defects of the CtAs of *dyrk1aa^krb1^* embryos were rescued by WT *dyrk1aa* mRNA injection. (E) The mean percentages of length and branching points of CtAs in *dyrk1aa^krb1^* mutants were rescued from 66.5% to 83.4% and from 61.2% to 108.3%, respectively, with 0.05 ng of *dyrk1aa* mRNA injection, relative to WT as 100%, and rescued to 89.9% and 122.0%, respectively, with 0.1 ng of *dyrk1aa* mRNA injection. Expression with 0.2 ng of *dyrk1aa* mRNA did not exhibit the rescue effect. Expression of *dyrk1aa* mRNA with the same doses in WT embryos also increased the length and branching points of CtAs in a dose-dependent manner (113.8% and 139.6% with 0.2 ng of *dyrk1aa* mRNA, respectively). \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.005 (one-way ANOVA). n.s., not significant. Data are mean±s.e.m. Scale bar: 100 µm in A; 50 µm in D.

DYRK1A regulates its target substrate proteins via phosphorylation ([@DMM037044C29]). To verify whether the cerebral hemorrhage and CtA defects in *dyrk1aa^krb1^* mutants were dependent on the kinase activity of Dyrk1aa, we performed rescue experiments with *K193R-dyrk1aa* mRNA, the predicted kinase-dead form of Dyrk1aa ([@DMM037044C34]). The expression of *K193R-dyrk1aa* mRNA or control mCherryRed mRNA failed to rescue the defects of hemorrhage and CtA formation with comparable doses of WT-*dyrk1aa* mRNA ([Fig. 3](#DMM037044F3){ref-type="fig"}B; [Fig. S4A and S4B](Fig. S4A and S4B)). These results suggest that the kinase activity of Dyrk1aa is critical for normal CtA development and prevention of hemorrhage.

Ultrastructural analyses of cerebral vessels in *dyrk1aa^krb1^* mutants by transmission electron microscopy {#s2d}
-----------------------------------------------------------------------------------------------------------

To examine whether the *dyrk1aa* mutation caused an ultrastructural change in brain vessels, we analyzed the cytoarchitecture of blood vessels in the WT and *dyrk1aa^krb1^* embryos at 52 hpf using transmission electron microscopy. In the WT group, blood vessels composed of endothelial cells and lumens were well formed and tightly arranged at this stage ([Fig. 4](#DMM037044F4){ref-type="fig"}A,A′), although smooth muscle cells, pericytes and astrocytes were in the process of differentiation and not yet clearly identified ([@DMM037044C47]). Characteristically, brain tissues in *dyrk1aa^krb1^* mutants exhibited enlarged interstitial spaces, presumably because of loose connections between layers of vessel walls (arrowheads in [Fig. 4](#DMM037044F4){ref-type="fig"}B,B′), suggesting that this abnormal formation of vessel walls was one of the causes of the hemorrhagic phenotype in *dyrk1aa^krb1^* mutant embryos. Fig. 4.**The transmission electron microscopy revealed that *dyrk1aa^krb1^* embryos had abnormal vessel walls in the brain at 52 hpf.** (A,B) Brain vessels in WT and *dyrk1aa^krb1^*. A′ and B′ show enlarged images of the boxed areas in A and B, respectively. (A′,B′) Arrows in A′ indicate the compact structure of vessel walls, whereas arrowheads in B′ designate the loose connection of vessel walls. Dashed lines demarcate the border between the vessel walls and the lumen. EC, endothelial cell; LM, vessel lumen; RBC, red blood cell; VW (dotted arrows), vessel wall. Scale bars: 1 µm.

DYRK1A inhibition by harmine and chemical screening {#s2e}
---------------------------------------------------

Cerebral angiogenic defects and hemorrhage in *dyrk1aa^krb1^* mutants were also recapitulated by harmine (7-methoxy-1-methyl-9H-pyrido\[3,4-b\]-indole), a well-known DYRK1A inhibitor ([@DMM037044C4]; [@DMM037044C25]). WT zebrafish embryos exposed to different concentrations of harmine (10, 25 and 50 µM) starting at 24 hpf for 28 h showed the hemorrhage and CtA formation defects at 52 hpf, similar to those of the *dyrk1aa^krb1^* mutants, and the number of CtA sprouts was reduced down to 15.2% of the control number at a concentration of 50 µM harmine ([Fig. 5](#DMM037044F5){ref-type="fig"}A,B). The harmine-induced hemorrhagic phenotype increased up to 65.7% that of the offspring, compared to 2.3% of the DMSO-treated controls ([Fig. 5](#DMM037044F5){ref-type="fig"}C). This chemical suppression of DYRK1A using harmine further suggested that the vascular phenotypes of *dyrk1aa^krb1^* mutants were owing to the loss of DYRK1A function. Fig. 5.**Inhibition of DYRK1A by harmine induces brain hemorrhage and vasculature defects in the hindbrain.** (A) WT *Tg(kdrl:EGFP)* embryos were treated with increasing concentrations of DYRK1A inhibitor harmine, from 24 hpf until 52 hpf: Aa, DMSO; Ab, 10 µM harmine; Ac, 25 µM harmine; Ad, 50 µM harmine. Vascular patterning defects of CtAs are shown (red brackets) by confocal imaging at 52 hpf (lateral view). (B) Quantification of the effect on number of developing CtAs by harmine treatment. The numbers of CtAs were dramatically reduced by treating harmine in a dose-dependent manner. *n*=11 each group. (C) Quantification of the brain hemorrhage penetrance. The cerebral hemorrhagic phenotype of 2.3% in DMSO-treated embryos was increased from 14.8% to 65.7% by harmine treatment from 10 µM to 50 µM. The mean percentage for each treatment was shown from three independent experiments with approximately 40 embryos in each repeat. (D) Schematic showing the strategy of the *in vivo* chemical library screening to identify small molecule modifiers for cerebral hemorrhagic phenotype upon DYRK1A inhibition. Data are mean±s.e.m. Scale bar: 100 µm.

Based on the hemorrhagic phenotype induced by harmine treatment, we developed an embryonic screening assay using a chemical library that consisted of 1280 FDA-approved and pharmacologically active compounds (LOPAC 1280; Sigma-Aldrich), which allowed us to identify small molecules that modulated the harmine-induced hemorrhagic phenotype. Five WT zebrafish embryos at 24 hpf were placed in each well of a 48-well plate, exposed to 30 µM harmine together with the individual chemicals of the chemical library at 10 µM as a final concentration for 28 h, and analyzed for the increased or decreased hemorrhagic phenotype ([Fig. 5](#DMM037044F5){ref-type="fig"}D). As a result, 171 of 1280 compounds tested were found to be phenotype modifiers, which were categorized according to their common features as 'class' based on their known functions ([Tables S1-S3](Tables S1-S3)). Some chemicals have already been reported to cause hemorrhage. For example, atorvastatin, which increased the hemorrhage in our screening, has been previously reported to induce hemorrhagic stroke as a side effect in zebrafish embryos ([@DMM037044C24]). Of the 171 compounds, EGTA, a specific calcium chelator, was identified as one of the most efficient suppressors of the hemorrhagic phenotype induced by harmine treatment, in our chemical screening.

EGTA effectively suppressed the vascular defects of *dyrk1aa^krb1^* mutants {#s2f}
---------------------------------------------------------------------------

To determine whether our findings from the chemical screening were applicable to the genetic model, we added EGTA to the *dyrk1aa^krb1^* mutants and examined the hemorrhagic and CtA development. Under heat-stressed conditions, the EGTA treatment significantly reduced the hemorrhagic phenotype of *dyrk1aa^krb1^* mutants at a specific concentration of 10 nM (from 37.5% to 23.6%, [Fig. 6](#DMM037044F6){ref-type="fig"}A,B; *P*\<0.05). In addition, a reduced CtA development of mutants in lengths and branching points (76% and 57.4% reduction compared to WT, respectively) was also rescued up to 86.6% and 85.9% of the normal levels, respectively, by treatment with the same concentrations of EGTA ([Fig. 6](#DMM037044F6){ref-type="fig"}C,D; *P*\<0.01). EGTA treatment appeared to be effective only within a narrow range, because 1 nM or 100 nM EGTA treatment failed to rescue the vascular defects of *dyrk1aa^krb1^* mutants, except for the rescue of CtA branching points with 1 nM EGTA ([Fig. 6](#DMM037044F6){ref-type="fig"}B,D). In contrast, EGTA treatment of the WT embryos did not induce any vascular defects ([Fig. S5](Fig. S5)), suggesting a specific role of EGTA on *dyrk1aa^krb1^* mutants. Fig. 6.**EGTA identified by the chemical library screening effectively rescues the cerebral hemorrhage and abnormal CtA development of *dyrk1aa^krb1^* mutants.** (A) *o*-dianisidine staining images at 52 hpf showing that the cerebral hemorrhage (arrow) of *dyrk1aa^krb1^* embryos were rescued by treating with 10 nM EGTA. WT embryos were not affected by the treatment at the same concentration. (B) Quantitation of the rescue of the cerebral hemorrhagic phenotype by EGTA. The cerebral hemorrhage in *dyrk1aa^krb1^* embryos is reduced from 37.5% to 23.6% by 10 nM EGTA treatment. The data is presented with five independent experiments with approximately 20 embryos in each repeat. (C) Compiled confocal microscopy images of the rescue effect on angiogenic defects of CtAs in *dyrk1aa^krb1^* embryos by EGTA treatment. (D) Quantitative data showing that the reduced mean percentages of length and branching points of CtAs in *dyrk1aa^krb1^* embryos at 52 hpf (76% and 57.4%, respectively, compared to WT embryos as 100%) were increased up to 86.6% and 85.9%, respectively, by 10 nM EGTA treatment. *n*≥11 each group. (E) Schematic depicts the treatment scheme of EGTA at developmental stages from 24 to 52 hpf in *dyrk1aa^krb1^* embryos. (F) The cerebral hemorrhage of *dyrk1aa^krb1^* embryos at 52 hpf (arrows) were rescued by 10 nM EGTA treatment for 24-32 hpf but not by the treatment for 32-48 hpf. (G) Quantitative data showing that cerebral hemorrhage of *dyrk1aa^krb1^* embryos reduced from 37.7% to 26.3% by treating with 10 nM EGTA for 24-32 hpf. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.005 (one-way ANOVA). n.s., not significant. Data are mean±s.e.m. Scale bars: 100 µm in A,F; 50 µm in C.

To identify the temporal requirement of EGTA for the suppressive effects, developing embryos were incubated with various doses of EGTA during an early period of 8 h (24∼32 hpf), followed by washing, or during a late period of 16 h (32∼48 hpf) ([Fig. 6](#DMM037044F6){ref-type="fig"}E). Interestingly, only the early treatment with 10 nM EGTA was effective in significantly preventing the cerebral hemorrhage (from 37.7% to 26.3%), whereas the early treatment with other doses and the late treatment was not ([Fig. 6](#DMM037044F6){ref-type="fig"}F,G). Because sprouting and elongation of cerebral vessels for angiogenesis occurs actively during day 1 postfertilization ([@DMM037044C22]; [@DMM037044C40]), EGTA may exert its suppressive effects on the vascular defects of *dyrk1aa^krb1^* mutants by regulating early angiogenic processes.

Transcriptomic analyses of *dyrk1aa^krb1^* mutants {#s2g}
--------------------------------------------------

Identification of EGTA as a suppressor of vascular defects in *dyrk1aa^krb1^* mutants by chemical screening implies that calcium signaling may be compromised in the *dyrk1aa^krb1^* mutants. To corroborate this finding, we examined transcriptomic changes of *dyrk1aa^krb1^* mutants compared to WT embryos at 48 hpf using RNA-seq analysis ([Fig. 7](#DMM037044F7){ref-type="fig"}). This analysis identified 222 transcripts as differentially regulated genes (DEG), of which 101 were upregulated and 121 were downregulated in the *dyrk1aa^krb1^* mutants (more than 2-fold and less than 0.5-fold, respectively; *P*\<0.05). When DEGs were analyzed for enriched biological gene ontology (GO) categories by the functional annotation tools in the Database for Annotation, Visualization and Integrated Discovery (DAVID; <https://david.ncifcrf.gov>), the calcium ion binding category was the most enriched GO molecular function (MF) ([Fig. 7](#DMM037044F7){ref-type="fig"}B). This GO category includes genes encoding several calcium-dependent adhesion proteins, protocadherin (Pcdh) family members (*pcdh1g1*, *pcdh2ab10*, *pcdh1gc6*, *pcdh2g17*, *pcdh1g18* and *pcdh1g30*) and calcium-dependent calpains (*capn8* and *capn2l*) ([@DMM037044C43]) ([Fig. 7](#DMM037044F7){ref-type="fig"}A). Other genes encoding myosin light chain 4 (*myl4*), low-density lipoprotein receptor b (*ldlrb*), and mannan-binding lectin serine protease 2 (*masp2*) in this GO term are also regulated by calcium signaling, directly or indirectly ([@DMM037044C42]; [@DMM037044C60]; [@DMM037044C88]) ([Fig. 7](#DMM037044F7){ref-type="fig"}A), although their roles in regulating vascular formation are not understood at present. In addition, the 'oxidation-reduction process', the top-ranked GO biological process (BP), is also well known to affect calcium signaling networks ([@DMM037044C26]; [@DMM037044C50]) ([Fig. 7](#DMM037044F7){ref-type="fig"}C), and the genes belonging to the 'homophilic cell adhesion via plasma membrane adhesion molecules' BP category consist of the six Pcdh family genes 'calcium ion binding' MF category ([Fig. 7](#DMM037044F7){ref-type="fig"}C). Fig. 7.**Whole transcriptomic analysis of *dyrk1aa^krb1^* compared with WT using RNA-seq.** (A) Volcano plot showing the comparison of the whole transcriptomes of the pools of ∼20 WT and *dyrk1aa^krb1^* embryos, set at 48 hpf (two biological replicates for each group). The colored dots show the differentially upregulated (red) or downregulated (blue) genes in *dyrk1aa^krb1^* embryos compared to WT embryos (more than 2-fold, *P*\<0.05). The colored dots with black circles indicate the upregulated (red dot with black circle) and downregulated (blue dot with black circle) genes in the group of 'calcium ion binding' (see text for details). (B) Bar graph showing the list of the groups of DEGs in the classification of the molecular functions. DEGs of the 'calcium ion binding' are most abundant. (C) Bar graph showing the list of the groups of DEGs in the classification of the biological process. DEGs of the 'oxidation-reduction process' are most abundant. Bar graph *x*-axis (B,C) represents the number of DEG counts in respective annotations.

We checked the validity of DEG identification by RNA-seq analysis with RT-PCR using RNAs from the whole embryos or from FACS-isolated endothelial cells at 48 hpf ([Fig. S6](Fig. S6)). As a result, nine out of 15 candidate DEGs (*pcdh1g1*, *pcdh2ab10*, *pcdh1gc6*, *myl4*, *pcdh1g18*, *f7i*, *capn8*, *pcdh1g30* and *capn2l*) were clearly changed in the whole *dyrk1aa^krb1^* mutant embryos ([Fig. S6A](Fig. S6A)). Those nine DEGs were further tested for expression changes in endothelial cells by performing another RT-PCR using RNAs prepared from FACS-isolated endothelial cells of 48 hpf *Tg(kdrl:EGFP)* WT and *dyrk1aa^krb1^* mutants. Seven DEGs (*pcdh1g1*, *pcdh2ab10*, *myl4*, *pcdh1g18*, *f7i*, *pcdh1g30* and *capn2l*) were found to be correlative with the similar patterns as in the whole embryos ([Fig. S6B](Fig. S6B)), suggesting their potential roles in *dyrk1aa*-mediated calcium signaling in endothelial cells.

In order to check whether calcium signaling changes occur even earlier than 48 hpf, especially when rescue by EGTA treatment is effective ([Fig. 6](#DMM037044F6){ref-type="fig"}), we also investigated the transcriptomic changes in *dyrk1aa^krb1^* mutants at 32 hpf using RNA-seq analysis ([Fig. S7](Fig. S7)). Similar to the findings of 48 hpf transcriptomic analysis, DEGs at 32 hpf were already highly enriched in the GO categories of 'calcium ion binding' and 'oxidoreductase activity' in MF ([Fig. S7A,B](Fig. S7A,B)). Furthermore, expression of six genes in the calcium ion binding category (*pcdh1g1*, *pcdh1g18*, *f7i*, *capn8*, *pcdh1g30* and *capn2l*) turned out to be concurrently changed in both 32 hpf and 48 hpf transcriptomes ([Fig. S7C](Fig. S7C)). Interestingly, five genes (*pcdh1g1*, *pcdh1g18*, *f7i*, *pcdh1g30* and *capn2l*) out of these six DEGs were also changed in the FACS-isolated endothelial cells ([Fig. S6B](Fig. S6B)), potentially highlighting their indispensability in *dyrk1aa*-mediated calcium signaling.

Collectively, alterations of genes in 'calcium ion binding' and other GO categories may reflect dysregulation of calcium homeostasis in *dyrk1aa^krb1^* mutants, consistent with the rescue effects by EGTA on vascular defects of mutants.

Modulation of intracellular calcium signaling also rescued vascular defects of *dyrk1aa^krb1^* mutants {#s2h}
------------------------------------------------------------------------------------------------------

As noted previously, EGTA is a chelating agent that has strong selectivity for calcium ions, primarily by lowering the level of extracellular calcium, eventually affecting the calcium homeostasis inside a cell, which is an essential process for regulating angiogenesis as well as other cellular processes including muscle contraction and neurogenesis ([@DMM037044C6]; [@DMM037044C58]). To assess whether the modulation of intracellular calcium signaling can recapitulate the effects of EGTA treatment, we attempted to rescue the cerebral hemorrhage and defective CtA formation of *dyrk1aa^krb1^* mutants by inhibiting calcineurin protein with FK506, a well-known specific calcineurin inhibitor ([@DMM037044C46]). The signaling pathway mediated by calcineurin, a serine/threonine protein phosphatase, is one of the major signaling pathways that is regulated by calcium ([@DMM037044C12]; [@DMM037044C36]). Interestingly, the hemorrhagic phenotype of *dyrk1aa^krb1^* was rescued by treatment with 50 and 100 ng/ml FK506 in a dose-dependent manner, whereas no significant change was observed in the WT control when treated ([Fig. 8](#DMM037044F8){ref-type="fig"}A,B). The same concentrations of FK506 also rescued defects in the CtA branching points (100 ng/ml) and length (50 ng/ml) of mutants, although FK506 also increased those of CtAs in the WT control ([Fig. 8](#DMM037044F8){ref-type="fig"}C,D). These data were consistent with the notion that the dysregulation of calcium homeostasis was responsible for the vascular defects of the *dyrk1aa^krb1^* mutants, and such defects could be rescued, at least partially, by manipulating a calcium-dependent signaling pathway. Fig. 8.**FK506 rescues the cerebral hemorrhage and CtA angiogenic defects in *dyrk1aa^krb1^* mutants.** (A) The cerebral hemorrhage of *dyrk1aa^krb1^* mutant embryos (arrows) was rescued by the treatment of 50 ng/ml FK506. (B) The cerebral hemorrhage in *dyrk1aa^krb1^* mutant embryos at 52 hpf (40.5%) was reduced to 17.8% and 13.4% by the treatment of 50 ng/ml and 100 ng/ml FK506, respectively. No differences were seen in WT with the same treatments. (C) The compiled confocal microscopy images of CtAs in the *Tg*(*kdrl:EGFP*) background showed that CtA defects in *dyrk1aa^krb1^* embryos were rescued by FK506 treatment in a dose-dependent manner, and CtA angiogenesis in WT was also affected. (D) The reduced mean percentage of CtA length of *dyrk1aa^krb1^* mutants (75.5%) was significantly rescued up to 84.6% by 50 ng/ml FK506, whereas that of mutant branching points (74.3%) was significantly rescued up to 96.4% by 100 ng/ml FK506 at 52 hpf, compared to WT embryos as 100%. 50 ng/ml FK506 treatment increased the WT CtA length up to 110.3%, whereas 100 ng/ml FK506 treatment increased both length and branching points of WT CtAs (109.5% and 133.8%, respectively). \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.005 (one-way ANOVA). n.s., not significant. Data are mean±s.e.m. Scale bars: 100 µm in A; 50 µm in C.

Modulation of calcium signaling by EGTA or FK506, however, did not reverse the transcriptional changes of DEGs found in transcriptomic analysis of *dyrk1aa^krb1^* mutants ([Fig. S8](Fig. S8)), implying that they may not be appropriate readouts for the phenotypic reversal. In addition, expression of potential zebrafish homologs of *RCAN1.4*, a known target gene in Dyrk1a/Calcineurin pathway ([@DMM037044C55]; [@DMM037044C70]), was not changed in *dyrk1aa^krb1^* mutants ([Fig. S9](Fig. S9)). These additional data suggest an involvement of more complex mechanisms *in vivo* with regard to calcium signaling regulated by *dyrk1aa*.

DISCUSSION {#s3}
==========

Proper cerebrovascular development and maintenance are essential processes for normal brain development and function, and are governed by diverse and coordinated signaling pathways ([@DMM037044C35]). In this report, we established a less-known function of *DYRK1A*, one of the critical genes contributing to some DS phenotypes, in regulating angiogenesis and preventing hemorrhage in the brain, using zebrafish *dyrk1aa* knockout mutants. The *in vivo* chemical screening using zebrafish embryos identified small molecules that were able to modify the cerebral hemorrhage upon DYRK1A inhibition. Among them, EGTA, a known specific calcium chelator, was identified as one of the most effective small molecules that rescued the vascular defects of *dyrk1aa* mutants. Changes in calcium-related signaling pathways revealed by RNA-seq analyses and the rescuing activity by chemical inhibition of calcineurin, a major component of the calcium-dependent pathway, on the vascular defects corroborated the notion that the vascular defects of *dyrk1aa* mutants were primarily due to calcium dysregulation, which could be reversed by inhibition of excessive calcium-dependent processes.

Zebrafish *dyrk1aa* knockout mutants exhibited compromised vessel integrity, with cerebral hemorrhage and angiogenesis simultaneously ([Figs 1](#DMM037044F1){ref-type="fig"} and [4](#DMM037044F4){ref-type="fig"}), compared to WT controls. Although the relationship between angiogenesis, vessel permeability and cerebral hemorrhage during developmental processes is not clearly defined, the interactions of these processes may be important for development of the functional cerebral vasculature. For example, a targeted deletion of miR-126 in mice showed that the cerebral hemorrhage due to defective vascular integrity accompanied a severe reduction in cranial vessel formation ([@DMM037044C85]). In addition, excessive angiogenesis was shown to precede the cerebral hemorrhage in the developing brain of neuroendothelium-specific *Itgb8* knockout mice ([@DMM037044C2]). Based on the mutant phenotypes described in our report, it is possible that DYRK1A may be a novel dual-function player that regulates both cerebral angiogenesis and the maintenance of vascular integrity simultaneously to prevent hemorrhage in the developing brain. Consistent with this idea, it has been reported that DS fetuses displayed several developmental vascular defects revealed by ultrasound scanning ([@DMM037044C9]), whereas DS adults suffered a significantly higher risk of hemorrhagic stroke, as shown in a large cohort study ([@DMM037044C74]), suggesting potential dual roles of *DYRK1A* in these vascular disorders.

*DYRK1A* function in angiogenesis and hemorrhage prevention is likely to be a calcium-dependent process, based on the comparative transcriptome analyses of the WT and *dyrk1aa* mutants ([Fig. 7](#DMM037044F7){ref-type="fig"}). The DEG analysis identified 'calcium ion binding' as the top-ranked GO category, which may reflect dysregulation of calcium homeostasis in *dyrk1aa* mutants. Of interest, several genes in the 'calcium ion binding' category have been associated with endothelial cell permeability and vascular dysfunction. For example, protocadherin genes such as the Pcdh-gamma cluster, one of the prominent groups of DEGs from our analysis, were recently reported to be highly expressed in endothelial cells of the brain microvasculature and may contribute to junctional stability of the blood-brain barrier ([@DMM037044C16]). Altered DEGs in the 'oxidoreductase activity' MF category and 'oxidation-reduction process' BP category in *dyrk1aa* mutants are also consistent with the disruption of Ca^2+^ signaling, because redox homeostasis is one of the major factors in regulating intracellular Ca^2+^ signaling events as well as vascular development ([@DMM037044C50]).

The calcium signal-related function of DYRK1A in cerebrovascular formation and maintenance is also supported by results from the *in vivo* chemical screening and calcineurin inhibition studies. The specific calcium chelator EGTA was identified as one of the most potent small molecules that rescued the cerebral hemorrhage elicited by DYRK1A inhibition ([Fig. 6](#DMM037044F6){ref-type="fig"}). The Ca^2+^ ion level inside the cytosol is normally maintained at a low concentration (approximately 100 nM), compared to a significantly higher (more than 20,000-fold) concentration in the extracellular environment ([@DMM037044C10]), illustrating the importance of the tight regulation of calcium homeostasis across the membrane in maintaining normal cellular functions. As EGTA is an extracellular calcium chelator, it may affect the calcium function either extracellularly by directly attenuating the activities of calcium-dependent extracellular vascular ligands and cell adhesion molecules ([@DMM037044C15]; [@DMM037044C81]), or intracellularly by lowering the amount of calcium entry into the cells. Our data suggested that both scenarios would be possible based on the facts that cerebral vessels in the mutants were disrupted at the ultrastructural level, presumably because of the altered calcium-dependent vascular integrity ([Fig. 4](#DMM037044F4){ref-type="fig"}), and rescue of the mutants\' vascular phenotypes were mimicked by inhibiting a calcium-dependent intracellular signaling pathway using FK506, a specific calcineurin inhibitor ([Fig. 8](#DMM037044F8){ref-type="fig"}). Consistent with these findings, dantrolene, a RyR antagonist that decreases the intracellular calcium level ([@DMM037044C21]), was also identified as a modestly effective small molecule in our chemical screening, although it did not reach statistical significance in our detailed analyses ([Table S3](Table S3) and data not shown).

An underlying mechanism by which DYRK1A regulates the calcium signaling in vascular formation is not yet clear. DYRK1A may affect Ca^2+^ flux directly, as in the case of GluN2A-containing N-methyl-D-aspartate glutamate receptor phosphorylation by DYRK1A, leading to the elevation of their density on the membrane, and eventually to neurological dysfunction ([@DMM037044C28]). Alternatively, DYRK1A may indirectly influence Ca^2+^ signaling by phosphorylating mediators that determine the expression or activity of calcium-dependent effectors, similar to myocardial pathology, in which phosphorylation of alternative splicing factor by DYRK1A increases the expression of Ca^2+^/calmodulin-dependent protein kinase II δ ([@DMM037044C33]). Because DYRK1A is likely to be functional both in the nucleus and in the cytoplasm, based on its ubiquitous localization at the cellular level ([@DMM037044C53]), it may directly or indirectly regulate membrane-bound ion channels near the cell membrane (similar to GluN2A phosphorylation), intracellular signaling molecules in the cytoplasm or transcription factors in the nucleus, eventually maintaining the Ca^2+^ homeostasis of cells.

Together, our characterization of zebrafish *dyrk1aa* knockout mutants showed that *DYRK1A* is implicated in cerebral angiogenic activity and the maintenance of vascular integrity during development. The combination of detailed transcriptomic analyses and chemical screening results strongly suggested that the calcium-dependent signaling regulated by *DYRK1A* is one of the major signaling pathways responsible for such vascular phenotypes. However, detailed signaling molecules and pathways affected in *dyrk1aa* mutants remain to be further studied. Our results also illustrate the usefulness of zebrafish *dyrk1aa* mutants in providing an *in vivo* animal model to understand the pathophysiology of human vascular diseases related to *DYRK1A* function and in suggesting potential therapeutic approaches for effective treatments.

MATERIALS AND METHODS {#s4}
=====================

Maintaining zebrafish embryos {#s4a}
-----------------------------

Zebrafish (*Danio rerio*) embryos of AB (WT) strain, transgenic zebrafish *Tg(kdrl:EGFP)* and *dyrk1aa* knockout mutant zebrafish (*dyrk1aa^krb1^*) were maintained in E3 egg water (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl~2~, 0.33 mM MgSO~4~) in a petri dish at 28.5°C. In order to generate transparent zebrafish embryos for imaging confocal microscopy, performing WISH and examining hemorrhagic phenotype, embryos were incubated in 1× PTU (0.003% 1-phenyl 2-thiourea, Sigma-Aldrich)-E3 egg water after 6 hpf. Zebrafish husbandry and animal care were performed in accordance with guidelines from the Korea Research Institute of Bioscience and Biotechnology (KRIBB) and approved by KRIBB-IACUC (approval number: KRIBB-AEC-17126).

*o*-Dianisidine staining and quantification of the hemorrhagic phenotype {#s4b}
------------------------------------------------------------------------

Embryos at 52 hpf were fixed with 4% paraformaldehyde in 1× phosphate-buffered saline (PBS) for 4 h at room temperature (RT) and washed with 1× PBS containing 0.1% Tween 20 (1× PBST). The embryos were placed in *o*-dianisidine stain solution \[0.6 mg/ml *o*-dianisidine (Sigma-Aldrich), 0.01 M sodium acetate (pH 5.5), 0.65% hydrogen peroxide and 40% ethanol\] in the dark for several minutes at RT to detect hemoglobin activity. *o*-Dianisidine is a peroxidase substrate, and hemoglobin catalyzes the H~2~O~2~-mediated oxidation of *o*-dianisidine. Stained embryos were washed several times with 1× PBST and stored in 70% glycerol for imaging using an Olympus SZX16 microscope equipped with TUCSEN Dhyana 400DC camera. The cerebral hemorrhagic phenotype was calculated as the mean percentages by counting the number of embryos with hemorrhagic phenotype in the brain and the retina.

FACS analysis of endothelial cells {#s4c}
----------------------------------

To isolate GFP-positive endothelial cells from *Tg(kdrl:EGFP)* embryos, we adopted the protocol developed by [@DMM037044C52]. Briefly, 150 embryos at 48 hpf were dechorionated with 1 mg/ml protease (P6911, Sigma-Aldrich) in E3 egg water for 5 min at RT, and washed in 0.5× Danieau\'s solution \[29 mM NaCl, 0.35 mM KCl, 0.2 mM MgSO~4~•7H~2~O, 0.3 mM Ca(NO~3~)~2~, 2.5 mM HEPES (pH 7.6)\]. The yolks of those embryos were removed using the deyolking buffer (55 mM NaCl, 1.8 mM KCl, 1.25 mM NaHCO~3~), followed by washing in 0.5× Danieau\'s solution, and embryonic cells were dissociated using FACS max cell dissociation solution (T200100, AMS Biotechnology) and the cell suspension passed through a 40 µm strainer (93040, SPL). FACS was performed at RT under sterile conditions using a FACSAria or FACSAria-Fusion (BD Biosciences).

RNA preparation and RT-PCR analysis {#s4d}
-----------------------------------

Zebrafish embryos in each developmental stage or cells isolated by FACS were harvested with TRI reagent solution (Ambion), followed by purifying total RNA with Direct-zol RNA miniprep kit (Zymo Research) and synthesizing cDNA with SuperScript III First-Strand Synthesis System (Invitrogen). The synthesized cDNA was amplified by PCR using: the forward primer 5′-TCAGTGATGCTCACCCACAG-3′ and reverse primer 5′-CGTCATAGCCGTCGTTGTAA-3′ for *dyrk1aa*; the forward primer 5′-GAAACGACGGCATCAACAGG-3′ and reverse primer 5′-CAGCTCGGTCGTAGGCTTTT-3′ for *dyrk1ab*; the forward primer 5′-GGCAAGCTGACCCTGAAGTT-3′ and reverse primer 5′-TTCTGCTTGTCGGCCATGAT-3′ for *EGFP*; the forward primer 5′-CCCTTACCCTGGCTTACACA-3′ and reverse primer 5′-TCTTGTTGGTTCCGTTCTCC-3′ for *kdrl*; and the forward primer 5′-CTGGTTCAAGGGATGGAAGA-3′ and reverse primer 5′-ATGTGAGCAGTGTGGCAATC-3′ for *eef1a1l1*. The RT-PCR primers used for supplementary figures are shown in [Table S4](Table S4).

Chemical treatment and small molecule library screening {#s4e}
-------------------------------------------------------

Harmine (Sigma-Aldrich) was dissolved in DMSO and added to 1× PTU-E3 egg water to earn final concentrations of 10-50 µM with 0.1% DMSO, and then applied to ∼40 embryos (dechorionated) on a 90 mm plate from 24 to 52 hpf.

For chemical screening, each of 1280 small molecules in the Library of Pharmacologically Active Compounds (LOPAC1280, Sigma-Aldrich) with 10 µM as a final concentration was individually applied into each well of 48-well plates containing 1× PTU-E3 egg water with 30 µM harmine and five embryos from 24 to 52 hpf. As a negative control, 1× PTU-E3 egg water containing 0.4% DMSO was used. Upon 30 µM harmine treatment, on average three embryos displayed the hemorrhage in the brain regions. Based on this criterion, the increased hemorrhage was defined by four or five embryos showing the hemorrhage in brain regions, whereas the reduced phenotype was defined by 0 to two embryos with such defect.

For EGTA and FK506 treatment, EGTA at final concentrations of 1-100 nM and FK506 at final concentrations of 5-100 ng/ml was applied into each well of 6-well plates containing ∼20 dechorionated embryos of WT and *dyrk1aa* mutants from 24 to 52 hpf, with 1× PTU-E3 egg water containing 0.1% DMSO alone used as a negative control.

Confocal microscopic analysis for cerebrovascular phenotypes of zebrafish embryos {#s4f}
---------------------------------------------------------------------------------

To analyze the brain vasculature phenotypes of *Tg(kdrl:EGFP)* embryos with high resolution, embryos were grown up to 52 hpf and fixed with 1× staining solution (4% paraformaldehyde, 4% sucrose, 0.15 mM CaCl~2~, 1× PBS) overnight at 4°C. Fixed embryos were washed briefly with 1× PBST and embedded on glass-bottomed imaging dishes with 1% low melting point agarose (Promega). The embryos were imaged using Olympus FV1000 confocal microscopy and the CtA development in the hindbrain was quantified using the length and branching points, by measuring total lengths with ImageJ and manually counting the junctional sites of the CtAs.

WISH and section of the hybridized embryos {#s4g}
------------------------------------------

WISH in zebrafish embryos was performed as previously reported ([@DMM037044C77]). The DNA templates for zebrafish *dyrk1aa*, *dyrk1ab* and *dll4* (GeneBank accession numbers BC129212.1, NM_001347831.1, and NM_001079835.1, respectively) were amplified from cDNA of WT embryos at 52 hpf. Prof. Cheol-Hee Kim (Chungnam National University, Republic of Korea) donated *kdrl*, *krox20* and *isl1* DNA. Dig-labeled anti-sense probes were *in vitro* transcribed using SP6 or T7 RNA polymerase kits (Roche) and purified with NucAway spin columns (Invitrogen). Embryos for WISH were prepared by fixing with 4% paraformaldehyde in 1× PBS, dehydrating using methanol, stored at −20°C for 30 min, and serially rehydrated using 1× PBST. The rehydrated embryos were treated with proteinase K in 1× PBS and post-fixed with 4% paraformaldehyde. The antisense probes were hybridized with the fixed embryos at each developmental stage in hybridizing solution (5 mg/ml torula yeast RNA type VI, 50 µg/ml heparin, 50% formamide, 5× SSC, 0.1% Tween-20, 1 M citric acid used to adjust to pH 6.0) at 70°C overnight. The probes were washed serially using 2× SSCT-F (2× SSCT, 50% formamide, 0.1% Tween-20), 2× SSCT (2× SSCT, 0.1% Tween-20), 0.2× SSCT (0.2× SSCT, 0.1% Tween-20) at 70°C and 1× PBST at RT. The embryos were blocked with blocking solution (5% horse serum, 1× PBST) at RT, and the alkaline phosphatase-conjugated anti-digoxigenin antibody (11 093 274 910, Roche) was added into the blocking solution at 4°C overnight. To detect the expression signal of transcripts, NBT/BCIP solution (11 681 451 001, Roche) was used as alkaline phosphatase substrate. The expression patterns of transcripts were observed using an Olympus SZX16 microscope and imaged with a TUCSEN Dhyana 400DC or Olympus XC10 camera. To observe detailed expression patterns, whole-mount RNA *in situ* hybridized embryos were prepared for cryosectioning by embedding in an agar-sucrose solution (1.5% agar, 5% sucrose). After the agar blocks containing the embryos were kept in 30% sucrose solution, they were processed for transverse cryosectioning using a LEICA CM1860 cryostat at a thickness of 25-35 µm.

Microinjection of RNA {#s4h}
---------------------

In order to prepare mRNAs of *dyrk1aa*, *dyrk1aa-K193R* and *mCherryRed* for rescue experiments, the pCS2+ vectors inserted with each DNA were linearized, *in vitro* transcribed using a mMESSAGE mMACHINE kit (Invitrogen) and purified with NucAway spin columns (Invitrogen). One-cell-stage eggs were collected and microinjected with each mRNA construct containing 0.05% Phenol Red solution as a visible indicator using a PV380 Pneumatic picopump (World Precision Instruments).

Transmission electron microscopy {#s4i}
--------------------------------

Tissue samples from embryos of WT and *dyrk1aa^krb1^* at 48 hpf were fixed immediately with 2% glutaraldehyde and 2% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) for 2 h at 4°C. Following three washes in the phosphate buffer, tissues were post-fixed with 1% osmium tetroxide on ice for 2 h and washed three times in the phosphate buffer. The tissues were then embedded in pure Epon 812 mixture after dehydration in ethanol series and followed by infiltration in propylene oxide:epon mixture series. Polymerization was conducted with pure resin at 70°C for 24 h. Ultrathin sections (∼70 nm) were obtained with a model MT-X ultramicrotome (RMC Boeckeler) and then collected on 100 mesh copper grids. After staining with 2% uranyl acetate (7 min) and lead citrate (2 min), the sections were visualized using the Bio-HVEM system (JEM-1400Plus at 120 kV and JEM-1000BEF at 1000 kV, JEOL).

Isolation, library preparation and sequencing for RNA-seq {#s4j}
---------------------------------------------------------

Total RNA was isolated using Trizol reagent (Invitrogen). RNA quality was assessed by an Agilent 2100 bioanalyzer using the RNA 6000 Nano Chip (Agilent Technologies), and RNA quantification was performed using an ND-2000 Spectrophotometer (Thermo Fisher Scientific). For control and test RNAs, the construction of the library was performed using the SENSE mRNA-Seq Library Prep Kit (Lexogen) according to the manufacturer\'s instructions. Briefly, 2 μg total RNA are prepared and incubated with magnetic beads decorated with oligo-dT, and other RNAs except mRNA were removed by washing, and the mRNA was isolated from the oligo-dT bead of the poly(A) RNA selection kit (Lexogen). Library production was initiated by the random hybridization of starter/stopper heterodimers containing Illumina-compatible linker sequences to the poly (A) RNA bound to the magnetic beads. A single-tube reverse transcription and ligation reaction extends the starter to the next hybridized heterodimer, where the newly synthesized cDNA insert is ligated to the stopper. Second strand synthesis was performed to release the library from the beads, and the library was then amplified. Barcodes were introduced when the library was amplified. High-throughput sequencing was performed as paired-end 100 sequencing using HiSeq 2500 (Illumina). The sequenced reads were mapped to the University of California Santa Cruz zebrafish genome ([danRer10](danRer10)) using STAR (v.2.5.1) ([@DMM037044C17]), and the gene expression levels were quantified using the count module in STAR. The edgeR (v.3.12.1) ([@DMM037044C69]) package was used to select differentially expressed genes from the RNA-seq count data. Meanwhile, the trimmed mean of M-values-normalized counts per million value of each gene was set to a baseline of 1 and log2-transformed for volcano plot drawing ([Figs 7](#DMM037044F7){ref-type="fig"}A and [S7A](S7A)).

Statistical analyses {#s4k}
--------------------

Statistical analyses of the data were performed using a Mann--Whitney *U* test or one-way ANOVA with Dunnett\'s multiple comparisons test using Prism software (Ver.7). Data are mean±s.e.m. with \**P*\<0.05, \*\**P*\<0.01 and \*\*\**P*\<0.005.
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